Henry Skinner has been promoted to CEO, from chief business officer, of NeoGenesis Pharmaceuticals, the company said today. He will also serve on the company's board of directors. Skinner replaces Satish Jindal, who stays on as NeoGenesis' CSO and chairman of its board. Prior to joining NeoGenesis last fall, Skinner was senior director for technology acquisitions and operations at Pfizer, working for its Pharmacia unit. Skinner holds a PhD in microbiology and a master's degree in biochemistry from the University of Illinois at Urbana-Champaign, as well as bachelor's and master's degrees in biology/biotechnology from Worcester Polytechnic Institute. NeoGenesis, based in Cambridge, Mass., is developing novel drug leads using chemical genomics.
Wes Davis has become CEO of Sionex, the company said yesterday. Prior to joining Sionex, he had been president of several technology companies. Sionex, founded in 2001 and based in Waltham, Mass., is developing chemical and biological sensor chips and systems.
W. Charles Montgomery has become vice president of business development at Atherogenics, the company said today. He succeeds John Mohr, who left the company "to pursue other business opportunities." Prior to joining Atherogenics, Montgomery was vice president of business development and portfolio planning at Celera Genomics. He holds a PhD in organic chemistry from the University of Minnesota and a BS in chemistry from Southern Methodist University.
Malcolm Maltby has become customer support manager for Farfield Sensors, the company said this week. He joins Farfield from Anachem, where he was responsible for maintenance and service of laboratory equipment. Also, Philip Onigman has joined SciPartners, Farfield Sensors' US distributor, to help generate instrument sales in the US. He joins the company from Genzyme Transgenics, where he was director of marketing. Farfield, based in Salford, UK, sells instruments for the analysis of proteins and other molecules based on dual polarization interferometry.
Axon Instruments promoted three employees to newly created vice presidential positions on Monday: Mike Catelani has become vice president and CFO, Chris Johnson vice president for hardware engineering, and Robert Wicke vice president for software engineering.
Catelani had been Axon's director of finance since 2002. Prior to joining the company, he was vice president of finance for Kirell Energy Systems. Catelani holds an MBA from the University of California, Davis, and a BSc in business administration/accountancy from California State University, Sacramento.
Johnson was promoted from director of hardware engineering. Before joining Axon, he was director of product engineering at Silicon Valley Group. Johnson holds an MS in electrical engineering and engineering management from Santa Clara University and two BS degrees, in mechanical and electrical engineering, from the University of California, Davis.
Wicke was promoted from director of software engineering. He holds an MS in mathematical visualization from the University of Oregon and a BA in mathematics and computer science from Drew University.
Jacob Plattner has become senior vice president of research and development at Anacor Pharmaceuticals, the company said on Monday. Before joining Anacor, he was vice president of small molecule discovery at Chiron. Plattner holds a PhD in organic chemistry from the University of California, Berkeley, and a BS from the University of Illinois. Anacor, based in Palo Alto, Calif., develops anti-infectives, including drugs against anthrax and tularemia.
Patrick Carroll has become chief business officer of BioTrove, the company said on Monday. He joins the company from Applied Biosystems, where he was senior vice president of worldwide sales. He holds MS and BA degrees in biological sciences from the University of Delaware and an MBA in marketing from Loyola College. BioTrove, of Woburn, Mass., develops nanofluidic biological assay platforms
Paulette Dillon has been appointed chief business officer of Celera Genomics, a unit of Applera, the company said on Monday. She comes to Celera from Exelixis Pharmaceuticals, where she was vice president for market and business development.
Mark Lotz has become vice president for regulatory affairs of MediciNova. Prior to joining the company, he held positions at Isis Pharmaceuticals, Amylin Pharmaceuticals, and Abbott Laboratories. Lotz has a BS in pharmacy from the St. Louis College of Pharmacy. MediciNova, of San Diego, Calif., is developing drugs for conditions like premature labor, cancer, and asthma.
Rajeev Dadoo has joined S.R. One as an associate, the company said last week. He holds a PhD in chemistry from Stanford University and an MBA from the Wharton School at the University of Pennsylvania. S.R. One, based in West Conshohocken, Pa., is a corporate life sciences venture fund is wholly owned by GlaxoSmithKline.
Clive Seymour has joined Bruker Daltonics, a unit of Bruker BioSciences, as vice president for Asia-Pacific, the company said last week. He joins Bruker from Biacore, where he was vice president for the region Asia Pacific.
Susan Berland has become interim CFO of Lynx Therapeutics, replacing Edward Albini, who resigned "to pursue another opportunity," the company said last week. Lynx is currently searching for a new CFO. Berland used to be CFO at DNA Sciences and had been consulting for Lynx in the past.
Kathryn Falberg and Augustine Lawlor have joined the board of directors of Human Genome Sciences, the company said today.
Falberg was CFO of Amgen until 2001. She holds an MBA and a BA in economics from the University of California, Los Angeles.
Lawlor is a general partner of HealthCare Ventures. He holds a master's degree in management from Yale University and a BA from the University of New Hampshire.
Stelios Papadopoulos has been appointed to the board of directors of Beyond Genomics, the company said yesterday. He is a vice chairman of SG Cowen Securities and covers biotechnology and the pharmaceutical industry as an investment banker. Papadopoulos holds a PhD in biophysics and an MBA in finance from New York University.
Jack Wyszomierski has been appointed to the board of directors of Exelixis, the company said on Monday. He was executive vice president and CFO of Schering-Plough until last year. Wyszomierski holds an MS in industrial administration and a BS in administration, management science, and economics from Carnegie Mellon University.
Lincoln Stein has won the 2004 Benjamin Franklin Award in Bioinformatics, the Bioinformatics Organization said last month. He will receive the award at the end of March for creating several open source bioinformatics programs and for supporting open source principles. Stein is a researcher at Cold Spring Harbor Laboratory.
Sir Edwin Southern of Oxford University received the 2004 Association of Biomolecular Resource Facilities award at the group's conference in Portland, Ore., on Monday. The award recognized his pioneering achievements in nucleic acid hybridization.
Jonathan Rothberg was elected to the National Academy of Engineering on Feb 13, CuraGen said last month. He is chairman, president, CEO and a founder of CuraGen. Rothberg's election to the academy honors his application of engineering principles to mining genomic information for drug discovery and development. He earned MS, MPhil, and PhD degrees in biology from Yale University and a BS in chemical engineering from Carnegie Mellon University.